-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec content team editor Recently, Ikena Oncology announced a clinical trial cooperation agreement with AstraZeneca.
The collaboration will evaluate the efficacy of AstraZeneca's third representative, the skin growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib (trade name: Teressa), in combination with Ikena's IK-930 to treat patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Lung cancer is the leading cause of cancer death in both men and women, accounting for about one-fifth
of all cancer deaths.
In EGFR-mutated (EGFRm) NSCLC, only 50% of patients resistant to osimertinib have potentially identifiable and actionable mechanisms and available therapies, and the remaining 50% have no definitive treatment options
.
This means that there is a huge unmet medical need
for this group of patients.
Ikena Oncology is a company
focused on developing drivers that target cancer formation and metastasis.
The company's primary targeted oncology product, IK-930, is a novel TEAD inhibitor that targets the Hippo signaling pathway
, one of the key drivers of cancer pathogenesis.
Of all cancer types, about 10 percent of patients have genetic alterations
in the Hippo pathway.
IK-930 binds to TEAD transcription factors to block the transcription
of multiple genes that promote cancer progression.
Currently, IK-930 is undergoing the first phase 1 clinical trial
in humans as monotherapy in patients with advanced solid tumors.
The FDA granted it fast-track designation
earlier this year.
Preclinical results suggest that IK-930 in combination with osimertinib can increase apoptosis and improve antitumor activity
in multiple EGFRm tumor models.
This benefit is mediated in part by the role of the Hippo pathway in the proliferation of persistent cells
.
This persistent cell is a subset of cancer cells that are able to develop EGFR resistance through TEAD-regulated cell cycle re-entry, DNAreplication, and related genes to avoid apoptosis
。 Under the clinical agreement, AstraZeneca will provide Ikena with osimertinib non-exclusively for efficacy evaluation
in combination with IK-930 in patients with EGFRm resistant NSCC.
Image credit: 123RF
Dr.
Mark Manfredi, CEO of Ikena, said: "Cancer patients with altered hippo pathways need treatments that are effective, safe and can significantly improve their quality of life
。 IK-930 is a specially designed TEAD inhibitor with the potential to provide patients with different treatment options
.
The selective nature of IK-930 has the potential to be used not only as monotherapy but also in combination with other targeted therapies where resistance has emerged, and it is a pleasure to explore combination therapy
with osimertinib with AstraZeneca.
" ”
The collaboration will evaluate the efficacy of AstraZeneca's third representative, the skin growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib (trade name: Teressa), in combination with Ikena's IK-930 to treat patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Lung cancer is the leading cause of cancer death in both men and women, accounting for about one-fifth
of all cancer deaths.
In EGFR-mutated (EGFRm) NSCLC, only 50% of patients resistant to osimertinib have potentially identifiable and actionable mechanisms and available therapies, and the remaining 50% have no definitive treatment options
.
This means that there is a huge unmet medical need
for this group of patients.
Ikena Oncology is a company
focused on developing drivers that target cancer formation and metastasis.
The company's primary targeted oncology product, IK-930, is a novel TEAD inhibitor that targets the Hippo signaling pathway
, one of the key drivers of cancer pathogenesis.
Of all cancer types, about 10 percent of patients have genetic alterations
in the Hippo pathway.
IK-930 binds to TEAD transcription factors to block the transcription
of multiple genes that promote cancer progression.
Currently, IK-930 is undergoing the first phase 1 clinical trial
in humans as monotherapy in patients with advanced solid tumors.
The FDA granted it fast-track designation
earlier this year.
Preclinical results suggest that IK-930 in combination with osimertinib can increase apoptosis and improve antitumor activity
in multiple EGFRm tumor models.
This benefit is mediated in part by the role of the Hippo pathway in the proliferation of persistent cells
.
This persistent cell is a subset of cancer cells that are able to develop EGFR resistance through TEAD-regulated cell cycle re-entry, DNAreplication, and related genes to avoid apoptosis
。 Under the clinical agreement, AstraZeneca will provide Ikena with osimertinib non-exclusively for efficacy evaluation
in combination with IK-930 in patients with EGFRm resistant NSCC.
Image credit: 123RF
Dr.
Mark Manfredi, CEO of Ikena, said: "Cancer patients with altered hippo pathways need treatments that are effective, safe and can significantly improve their quality of life
。 IK-930 is a specially designed TEAD inhibitor with the potential to provide patients with different treatment options
.
The selective nature of IK-930 has the potential to be used not only as monotherapy but also in combination with other targeted therapies where resistance has emerged, and it is a pleasure to explore combination therapy
with osimertinib with AstraZeneca.
" ”
"Expanding the number of patients who can benefit from targeted oncology therapy is an important goal
for our team.
By understanding the mechanisms by which cancer cells resist treatment, we can create genes that block their key compensatory survival pathway with combination therapies," commented Dr.
Jeffrey Ecsedy, Chief Development Officer at Ikena.
"Collaborating with AstraZeneca will allow us to explore how IK-930 can benefit patients with EGFR-mutated cancers that are currently resistant to monotherapy, and demonstrate how combining with IK-931 can achieve a deeper, longer-lasting anti-tumor response
.
" ”
WuXi AppTec provides integrated, end-to-end new drug R&D and manufacturing services to the global biopharmaceutical industry, covering chemical drug R&D and manufacturing, biological research, preclinical testing and clinical trial R&D, cell and gene therapy R&D, testing and manufacturing
.
If you have related business needs, please click the picture below to fill in the specific information
.
